

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=1; day=30; hr=12; min=5; sec=23; ms=105;]

=====

Application No: 10540431

Version No: 2.1

Input Set:

Output Set:

Started: 2008-01-30 12:03:21.668

Finished: 2008-01-30 12:03:24.765

Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 97 ms

Total Warnings: 18

Total Errors: 8

No. of SeqIDs Defined: 18

Actual SeqID Count: 18

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
E 257	Invalid sequence data feature in <221> in SEQ ID (18)
E 257	Invalid sequence data feature in <221> in SEQ ID (18)

Input Set:

Output Set:

Started: 2008-01-30 12:03:21.668

Finished: 2008-01-30 12:03:24.765

Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 97 ms

Total Warnings: 18

Total Errors: 8

No. of SeqIDs Defined: 18

Actual SeqID Count: 18

[illegible]

<110> KULSETH, MARI ANN

<120> PEPTIDES THAT BIND TO THE HEPARIN BINDING DOMAIN OF
VEGF AND VEGFR-2

<130> PN0273

<140> 10540431

<141> 2005-06-22

<150> PCT/NO03/00444

<151> 2003-12-29

<150> NO 20026286

<151> 2002-12-30

<160> 18

<170> PatentIn Ver. 3.3

<210> 1

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1

Cys Ser Tyr Tyr Ser Asp Gly Val Tyr Asp Cys

1 5 10

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2

Cys His Tyr Ser Ser Asp Gly Thr Tyr Asp Cys

1 5 10

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

peptide

<400> 3

Cys Thr Tyr Asn Gly Asp Gly Ser Phe Asp Cys
1 5 10

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 4

Cys Ala Tyr Glu Ala Asp Gly Trp Phe Asp Cys
1 5 10

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5

Cys Ser Tyr Ser Ala Asp Gly Thr Leu Asp Cys
1 5 10

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 6

Cys Gln Tyr Asp Ser Ser Gly Met Tyr Asp Cys
1 5 10

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 7

Cys Phe Phe Asp Ser Ser Gly Tyr Phe Asp Cys

1 5 10

<210> 8

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 8

Cys Thr Tyr Ser Ala Asp Gly Leu Tyr Asp Cys

1 5 10

<210> 9

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 9

Cys His Phe Asp Gly Asp Gly Ser Tyr Asp Cys

1 5 10

<210> 10

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 10

Cys Thr Tyr Glu Pro Ser Gly Met Tyr Asp Cys

1 5 10

<210> 11

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 11

Cys Gln Tyr Thr Ala Asp Gly Ala Phe Asp Cys

1 5 10

<210> 12

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 12

Cys Ile Tyr Glu Ser Asp Gly Met Phe Ser Cys

1 5 10

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 13

Cys Gly Arg Ser Asp Gly Thr Trp Tyr Glu Cys

1 5 10

<210> 14

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 14

Cys Ser Tyr Tyr Ala Asp Gly Met Tyr Ser Cys

1 5 10

<210> 15

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 15

Ser Tyr Tyr Ser Asp Gly Val Tyr Asp Cys Gly Cys
1 5 10

<210> 16

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 16

Ala Glu Gly Glu Phe Cys Ser Tyr Tyr Ser Asp Gly Val Tyr Asp Cys
1 5 10 15

Gly Cys

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 17

Cys Ser Tyr Tyr Ser Asp Gly Val Tyr Asp Cys Gly Cys
1 5 10

<210> 18

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (1)

<223> Any amino acid residue capable of forming a
disulphide bond, preferably a cysteine or a
homocysteine residue, or a residue capable of
forming a thioether or absent

<220>

<221> MOD_RES

<222> (2)

<223> Ser, His, Thr, Ala, Gln, Phe, Gly or Ile

<220>
 <221> MOD_RES
 <222> (4)
 <223> Tyr, Ser, Asn, Glu, Asp or Thr

<220>
 <221> MOD_RES
 <222> (5)
 <223> Ala or Ser

<220>
 <221> MOD_RES
 <222> (8)
 <223> Thr, Val, Met, Ser, Trp, Tyr, Leu or Ala

<220>
 <221> MOD_RES
 <222> (9)
 <223> Tyr or Phe

<220>
 <221> MOD_RES
 <222> (11)
 <223> Any amino acid residue capable of forming a
 disulphide bond, preferably a cysteine or a
 homocysteine residue or absent

<220>
 <221> MOD_RES
 <222> (12)..(21)
 <223> Variable amino acid and this region may encompass
 0 to 10 residues

<220>
 <223> See specification as filed for detailed description of
 substitutions and preferred embodiments

<400> 18
 Xaa Xaa Tyr Xaa Xaa Asp Gly Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

 Xaa Xaa Xaa Xaa Xaa
 20